arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PALVELLA THERAPEUTICS, INC.

PVLA
$156.30 ▼ -6.35 (-3.91%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

PALVELLA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2B
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -9.9% ↘
FCF / Share $-0.89 ↘
Trailing P/E —
Price / Book 10.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$53.00K
↓ -97.3% —
Net Income Profit after all expenses
$-15.77M
↓ -92.6% —
Operating Margin Operating profit as % of sales
-60.5%
↓ -688.0% —
FCF / Share Free cash flow per share
$-0.89
↓ -7.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
5
Cash Quality ↑
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 55 quarters